JOINN Laboratories acquired Biomere in 2019, creating a globally integrated drug development CRO service offering. Biomere’s non-GLP PK/PD and early toxicology services complement JOINN’s full GLP toxicology and clinical trial support capabilities, enabling seamless program progression from discovery through IND-enabling studies.
Biotech and pharma sponsors benefit from flexible study placement options that can reduce costs and accelerate timelines, including the opportunity to conduct studies in China while maintaining high scientific and regulatory standards.
JOINN is the largest GLP preclinical CRO in China, with major facilities in Suzhou, Beijing, Wuzhou, Chongqing, and Guangzhou, providing global scale and expertise to advance nonclinical drug development programs.
JOINN Laboratories holds the following accreditations, certifications and inspections:
Visit the JOINN Laboratories website – https://www.joinnlabs.com/ to learn more and connect with a team member.
